GCC-4001 is under clinical development by Artiva Biotherapeutics ... It is investigating AB-101, an allogeneic NK cell therapy used for the treatment of B-cell malignancies; AB-201, a CAR-NK (chimeric ...
For a complete picture of GCC-4001’s drug-specific PTSR and LoA scores, buy the report here. GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback